RU2007132977A - Способ лечения и предупреждения потери костной ткани - Google Patents
Способ лечения и предупреждения потери костной ткани Download PDFInfo
- Publication number
- RU2007132977A RU2007132977A RU2007132977/15A RU2007132977A RU2007132977A RU 2007132977 A RU2007132977 A RU 2007132977A RU 2007132977/15 A RU2007132977/15 A RU 2007132977/15A RU 2007132977 A RU2007132977 A RU 2007132977A RU 2007132977 A RU2007132977 A RU 2007132977A
- Authority
- RU
- Russia
- Prior art keywords
- lipoxygenase
- mammal
- bone
- effectiveness
- lipoxygenase inhibitor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 41
- 210000000988 bone and bone Anatomy 0.000 title claims abstract 10
- 230000002265 prevention Effects 0.000 title 1
- 206010065687 Bone loss Diseases 0.000 claims abstract 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000011575 calcium Substances 0.000 claims abstract 3
- 229910052791 calcium Inorganic materials 0.000 claims abstract 3
- 230000011164 ossification Effects 0.000 claims abstract 2
- 229940123153 15 Lipoxygenase inhibitor Drugs 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 claims 9
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 7
- 238000012544 monitoring process Methods 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 238000010230 functional analysis Methods 0.000 claims 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 3
- 239000011707 mineral Substances 0.000 claims 3
- KRDSGPLHVQJFLM-BUHFOSPRSA-N (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid Chemical compound CCCCCCC#CC1=CC=CC=C1\C=C\C(O)=O KRDSGPLHVQJFLM-BUHFOSPRSA-N 0.000 claims 2
- LNXMHXYXZGNPFI-UHFFFAOYSA-N 3-(2-non-1-ynylphenyl)propanoic acid Chemical compound CCCCCCCC#CC1=CC=CC=C1CCC(O)=O LNXMHXYXZGNPFI-UHFFFAOYSA-N 0.000 claims 2
- ZKXFJDCWWSKUHN-UHFFFAOYSA-N 3-amino-n-(3,4-dichlorophenyl)-4-methoxybenzamide Chemical compound C1=C(N)C(OC)=CC=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 ZKXFJDCWWSKUHN-UHFFFAOYSA-N 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- ZGOOPZVQMLHPFM-UHFFFAOYSA-N PD-146176 Chemical compound N1C2=CC=CC=C2C2=C1C1=CC=CC=C1SC2 ZGOOPZVQMLHPFM-UHFFFAOYSA-N 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- -1 isobutyl ether [[[5- ( 5,6-difluoro-1H-indol-2-yl) -2-methoxyphenyl] amino] sulfonyl] carbamic acid Chemical compound 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
Claims (25)
1. Способ идентификации соединений, которые обладают способностью увеличивать минеральную плотность костной ткани, заключающийся в том, что соединение приводят в контакт с 15-липоксигеназой и определяют, обладает ли соединение активностью в отношении ингибирования 15-липоксигеназы.
2. Способ по п.1, отличающийся тем, что соединение тестируют с помощью функционального анализа, который позволяет определять эффективность соединения в отношении формирования костной ткани.
3. Способ по п.2, в котором функциональный анализ заключается в том, что соединение приводят в контакт с человеческими мезенхимальными стволовыми клетками и определяют дифференцировку клеток в костеобразующие клетки.
4. Способ по п.2, в котором функциональный анализ заключается в том, что соединение вводят животному кроме человека и измеряют индекс костеобразования.
5. Способ по п.4, в котором измеряемый индекс представляет собой минеральную плотность костной ткани.
6. Способ по п.4, в котором индекс представляет собой биомеханический параметр кости.
7. Способ по п.3, в котором для определения дифференцировки клеток проводят анализ щелочной фосфатазы, анализ содержания кальция, анализ общей ДНК препарата или их комбинацию.
8. Способ мониторинга эффективности способа уменьшения потери костной ткани у млекопитающего, который предусматривает введение пациенту эффективного количества ингибитора 15-липоксигеназы, заключающийся в том, что измеряют уровень 15-липоксигеназы у индивидуума.
9. Способ по п.8, где потеря костной ткани связана с остеопорозом, остеоартритом, болезнью Пэджета или заболеваниями периодонта.
10. Способ по п.9, где потеря костной ткани связана с остеопорозом.
11. Способ мониторинга эффективности способа увеличения минеральной плотности костной ткани у млекопитающего, который предусматривает введение млекопитающему эффективного количества ингибитора 15-липоксигеназы, заключающийся в том, что измеряют уровень 15-липоксигеназы у индивидуума.
12. Способ мониторинга эффективности способа уменьшения количества случаев перелома у млекопитающего, который предусматривает введение млекопитающему эффективного количества ингибитора 15-липоксигеназы, заключающийся в том, что измеряют уровень 15-липоксигеназы у индивидуума.
13. Способ мониторинга эффективности способа заживления переломов у млекопитающего, который предусматривает введение млекопитающему эффективного количества ингибитора 15-липоксигеназы, заключающийся в том, что измеряют уровень 15-липоксигеназы у индивидуума.
14. Способ мониторинга эффективности способа лечения остеопороза у млекопитающего, который предусматривает введение млекопитающему эффективного количества ингибитора 15-липоксигеназы, заключающийся в том, что измеряют уровень 15-липоксигеназы у индивидуума.
15. Способ по одному из пп.8-14, где млекопитающее представляет собой человека.
16. Способ по п.15, где ингибитор 15-липоксигеназы имеет значение IC50 менее 1 мкМ.
17. Способ по п.8, предусматривающий, кроме того, использование дополнительного действующего вещества.
18. Способ по п.17, где дополнительное действующее вещество обладает активностью в отношении регуляции резорбции кальция из костной ткани.
19. Способ по п.18, где дополнительное действующее вещество выбирают из ряда, включающего эстроген, кальцитонин, бисфосфонаты и IGF.
20. Способ по одному из пп.8-14 и 16-19, где ингибитор 15-липоксигеназы выбирают из ряда, включающего синтетические органические молекулы, природные продукты и антитела.
21. Способ по п.15, где ингибитор 15-липоксигеназы выбирают из ряда, включающего синтетические органические молекулы, природные продукты и антитела.
22. Способ по одному из пп.8-14 и 16-19, где ингибитор 15-липоксигеназы выбирают из ряда, включающего 3-(2-нон-1-инилфенил)пропионовую кислоту, 6,11-дигидро-5-тиа-11-азабензо[а]флуорен, 3-амино-N-(3,4-дихлорфенил)-4-метоксибензамид, транс-3-(2-окт-1-инилфенил)акриловую кислоту и изобутиловый эфир [[[5-(5,6-дифтор-1Н-индол-2-ил)-2-метоксифенил]амино]сульфонил]карбаминовой кислоты.
23. Способ по п.15, где ингибитор 15-липоксигеназы выбирают из ряда, включающего 3-(2-нон-1-инилфенил)пропионовую кислоту, 6,11-дигидро-5-тиа-11-азабензо[а]флуорен, 3-амино-N-(3,4-дихлорфенил)-4-метоксибензамид, транс-3-(2-окт-1-инилфенил)акриловую кислоту и изобутиловый эфир [[[5-(5,6-дифтор-1Н-индол-2-ил)-2-метоксифенил]амино]сульфонил]карбаминовой кислоты.
24. Способ мониторинга эффективности способа стимуляции дифференцировки мезинхимальных стволовых клеток у человека в остеобласты, который предусматривает введение человеку эффективного количества ингибитора 15-липоксигеназы, заключающийся в том, что измеряют уровень 15-липоксигеназы у индивидуума.
25. Способ по п.24, где ингибитор 15-липоксигеназы имеет значение IC50 менее 1 мкМ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35525502P | 2002-02-08 | 2002-02-08 | |
| US60/355,255 | 2002-02-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004127131/15A Division RU2319483C2 (ru) | 2002-02-08 | 2003-02-03 | Способ лечения и предупреждения потери костной ткани |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007132977A true RU2007132977A (ru) | 2009-03-10 |
| RU2358728C2 RU2358728C2 (ru) | 2009-06-20 |
Family
ID=27734489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004127131/15A RU2319483C2 (ru) | 2002-02-08 | 2003-02-03 | Способ лечения и предупреждения потери костной ткани |
| RU2007132977/15A RU2358728C2 (ru) | 2002-02-08 | 2007-09-03 | Способ лечения и предупреждения потери костной ткани |
| RU2007132981/15A RU2007132981A (ru) | 2002-02-08 | 2007-09-03 | Способ лечения и предупреждения потери костной ткани |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004127131/15A RU2319483C2 (ru) | 2002-02-08 | 2003-02-03 | Способ лечения и предупреждения потери костной ткани |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007132981/15A RU2007132981A (ru) | 2002-02-08 | 2007-09-03 | Способ лечения и предупреждения потери костной ткани |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20030175680A1 (ru) |
| EP (3) | EP1634618B1 (ru) |
| JP (1) | JP2005531498A (ru) |
| KR (2) | KR100589819B1 (ru) |
| CN (3) | CN1287789C (ru) |
| AT (1) | ATE385835T1 (ru) |
| AU (1) | AU2003206822C1 (ru) |
| BR (1) | BR0307522A (ru) |
| CA (2) | CA2697599A1 (ru) |
| DE (1) | DE60319156T2 (ru) |
| ES (1) | ES2299923T3 (ru) |
| MX (1) | MXPA04007611A (ru) |
| PL (1) | PL372228A1 (ru) |
| RU (3) | RU2319483C2 (ru) |
| WO (1) | WO2003066048A2 (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8639009B2 (en) * | 2000-10-11 | 2014-01-28 | Imatx, Inc. | Methods and devices for evaluating and treating a bone condition based on x-ray image analysis |
| US7660453B2 (en) | 2000-10-11 | 2010-02-09 | Imaging Therapeutics, Inc. | Methods and devices for analysis of x-ray images |
| US8000766B2 (en) | 2001-05-25 | 2011-08-16 | Imatx, Inc. | Methods to diagnose treat and prevent bone loss |
| US8965075B2 (en) | 2002-09-16 | 2015-02-24 | Imatx, Inc. | System and method for predicting future fractures |
| US7840247B2 (en) | 2002-09-16 | 2010-11-23 | Imatx, Inc. | Methods of predicting musculoskeletal disease |
| US7664298B2 (en) | 2003-03-25 | 2010-02-16 | Imaging Therapeutics, Inc. | Methods for the compensation of imaging technique in the processing of radiographic images |
| US20080058613A1 (en) * | 2003-09-19 | 2008-03-06 | Imaging Therapeutics, Inc. | Method and System for Providing Fracture/No Fracture Classification |
| GB0410103D0 (en) * | 2004-05-06 | 2004-06-09 | Biolipox Ab | New method |
| WO2005123130A2 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
| EP1789924A2 (en) | 2004-09-16 | 2007-05-30 | Imaging Therapeutics, Inc. | System and method of predicting future fractures |
| US20070036770A1 (en) * | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
| JP2009504776A (ja) * | 2005-08-18 | 2009-02-05 | アクセラロクス， インコーポレイテッド | アラキドン酸代謝経路またはシグナル伝達経路を調節することによる骨を処置するための方法 |
| US20090247634A1 (en) * | 2006-06-27 | 2009-10-01 | Hans-Erik Claesson | Methods for identifying modulators of eoxin formation |
| US20080076836A1 (en) * | 2006-09-01 | 2008-03-27 | Cardiac Pacemakers, Inc | Method and apparatus for using light to enhance cell growth and survival |
| US20080200425A1 (en) * | 2007-02-16 | 2008-08-21 | Kurtz Seymour J | Methods and compositions for regulating bone mineral density |
| EP2142924A2 (en) * | 2007-04-26 | 2010-01-13 | President And Fellows Of Harvard College | Assays for the identification of compounds that modulate bone formation and mineralization |
| WO2009105723A2 (en) * | 2008-02-22 | 2009-08-27 | Accelalox, Inc. | Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| US8939917B2 (en) | 2009-02-13 | 2015-01-27 | Imatx, Inc. | Methods and devices for quantitative analysis of bone and cartilage |
| US20110136728A1 (en) * | 2009-12-09 | 2011-06-09 | Patricia Grasso | Methods of increasing bone formation using leptin-related peptides |
| WO2011088163A1 (en) | 2010-01-14 | 2011-07-21 | President And Fellows Of Harvard College | Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination |
| CN102138961A (zh) * | 2010-02-02 | 2011-08-03 | 北京绿色金可生物技术股份有限公司 | 黑豆皮提取物在预防和治疗骨关节炎的产品中的应用 |
| KR101474053B1 (ko) | 2011-04-08 | 2014-12-19 | 울산대학교 산학협력단 | 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커 |
| RU2517037C1 (ru) * | 2013-02-08 | 2014-05-27 | Евгений Викторович Ларионов | Способ получения костного минерального компонента и костный минеральный компонент для замещения и восстановления дефектов костной ткани |
| EP3036226B1 (en) | 2013-08-22 | 2020-01-08 | The General Hospital Corporation | Inhibitors of human 12/15-lipoxygenase |
| EP3159003A3 (en) * | 2015-10-23 | 2017-07-19 | Universiti Putra Malaysia | Composition for enhancing bone growth, preventing bone resorption disorders and for joint health |
| CN106405064B (zh) * | 2016-08-30 | 2018-10-26 | 嘉兴行健生物科技有限公司 | 一种40岁以上女性骨转换率的评估方法 |
| CN108251454A (zh) * | 2017-12-26 | 2018-07-06 | 温州医科大学附属第医院 | 一种脂氧合酶基因修饰间充质干细胞的获取方法及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA838339B (en) * | 1982-11-11 | 1985-06-26 | Beecham Group Plc | Novel arachidonic acid analogues and pharmaceutical compositions containing them |
| DE3360677D1 (en) | 1982-11-11 | 1985-10-03 | Beecham Group Plc | Arachidonic acid analogues, processes for their preparation and their use in medicine |
| US4605669A (en) | 1985-04-26 | 1986-08-12 | Abbott Laboratories | Lipoxygenase inhibiting naphthohydroxamic acids |
| US4623661A (en) * | 1985-04-26 | 1986-11-18 | Abbott Laboratories | Lipoxygenase inhibiting compounds |
| US4761403A (en) * | 1986-04-09 | 1988-08-02 | Abbott Laboratories | Lipoxygenase inhibiting compounds |
| US4873259A (en) | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
| EP0540673B1 (en) * | 1990-07-25 | 1996-10-16 | Abbott Laboratories | Acetylene derivatives having lipoxygenase inhibitory activity |
| US5478579A (en) * | 1991-02-06 | 1995-12-26 | Biodyn Medical Research, Inc. | Method for treatment of osteoporosis |
| US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| US5641747A (en) * | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
| US5620997A (en) * | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| US5717062A (en) | 1995-06-07 | 1998-02-10 | Beth Israel Hospital Association | Cyclic analogs of PTH and PTHrP |
| US5972980A (en) * | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| AU6966696A (en) * | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6268387B1 (en) * | 1997-12-23 | 2001-07-31 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| WO2001096298A2 (en) * | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
-
2003
- 2003-02-03 EP EP05014630A patent/EP1634618B1/en not_active Expired - Lifetime
- 2003-02-03 CN CNB038035375A patent/CN1287789C/zh not_active Expired - Fee Related
- 2003-02-03 EP EP05014631A patent/EP1666883A1/en not_active Withdrawn
- 2003-02-03 RU RU2004127131/15A patent/RU2319483C2/ru not_active IP Right Cessation
- 2003-02-03 MX MXPA04007611A patent/MXPA04007611A/es active IP Right Grant
- 2003-02-03 AT AT05014630T patent/ATE385835T1/de not_active IP Right Cessation
- 2003-02-03 KR KR1020047012298A patent/KR100589819B1/ko not_active IP Right Cessation
- 2003-02-03 BR BR0307522-2A patent/BR0307522A/pt not_active IP Right Cessation
- 2003-02-03 PL PL03372228A patent/PL372228A1/xx not_active Application Discontinuation
- 2003-02-03 EP EP03704519A patent/EP1476153A2/en not_active Withdrawn
- 2003-02-03 CA CA2697599A patent/CA2697599A1/en not_active Abandoned
- 2003-02-03 CA CA002474431A patent/CA2474431A1/en not_active Abandoned
- 2003-02-03 CN CNB2006101000659A patent/CN100410388C/zh not_active Expired - Fee Related
- 2003-02-03 KR KR1020067005947A patent/KR100653017B1/ko not_active IP Right Cessation
- 2003-02-03 ES ES05014630T patent/ES2299923T3/es not_active Expired - Lifetime
- 2003-02-03 CN CNA2006101078189A patent/CN1936023A/zh active Pending
- 2003-02-03 JP JP2003565472A patent/JP2005531498A/ja not_active Ceased
- 2003-02-03 DE DE60319156T patent/DE60319156T2/de not_active Expired - Lifetime
- 2003-02-03 AU AU2003206822A patent/AU2003206822C1/en not_active Ceased
- 2003-02-03 WO PCT/EP2003/001033 patent/WO2003066048A2/en active Application Filing
- 2003-02-07 US US10/361,093 patent/US20030175680A1/en not_active Abandoned
-
2005
- 2005-11-23 US US11/286,237 patent/US20060079488A1/en not_active Abandoned
-
2007
- 2007-09-03 RU RU2007132977/15A patent/RU2358728C2/ru not_active IP Right Cessation
- 2007-09-03 RU RU2007132981/15A patent/RU2007132981A/ru unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007132977A (ru) | Способ лечения и предупреждения потери костной ткани | |
| Jadhav et al. | Statins and osteoporosis: new role for old drugs | |
| Khadra et al. | Effect of laser therapy on attachment, proliferation and differentiation of human osteoblast-like cells cultured on titanium implant material | |
| Meadows et al. | Effect of weight-bearing on healing of cortical defects in the canine tibia. | |
| Galler et al. | Pathophysiological mechanisms of root resorption after dental trauma: a systematic scoping review | |
| Ozawa et al. | Low-energy laser irradiation stimulates bone nodule formation at early stages of cell culture in rat calvarial cells | |
| O'Sullivan et al. | Experimental study of the effect of weight bearing on fracture healing in the canine tibia. | |
| ATE295734T1 (de) | Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums | |
| ATE269102T1 (de) | Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums | |
| US20020161026A1 (en) | Combination therapies for the stimulation of bone growth | |
| Li et al. | c-Fos expression in the medulla induced by static muscle contraction in cats | |
| Weiss et al. | Systemic regulation of angiogenesis and matrix degradation in bone regeneration—distraction osteogenesis compared to rigid fracture healing | |
| Landry et al. | Electromagnetic fields can affect osteogenesis by increasing the rate of differentiation. | |
| Bauss et al. | New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate | |
| Ozawa et al. | Stimulatory effects of low-power laser irradiation on bone formation in vitro | |
| Allen et al. | Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate | |
| BR0314081A (pt) | Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase | |
| Norton et al. | Bioelectric perturbations of bone: Research directions and clinical applications | |
| Ammann et al. | The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats | |
| Gebken et al. | Increased cell surface expression of receptors for transforming growth factor-β on osteoblasts from patients with Osteogenesis imperfecta | |
| DE60224429D1 (de) | Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol | |
| Gruber et al. | Osteoblast numbers after calcitonin therapy: A retrospective study of paired biopsies obtained during long-term calcitonin therapy in postmenopausal osteoporosis | |
| Feldman et al. | Geranylgeraniol in Bone Cement Rescues Osteoclasts from the Toxic Effects of Pamidronate and Restores Function | |
| Cardoso et al. | Naringenin and proanthocyanidins pre-treatment decreases synthesis and activity of gelatinases induced by zoledronic acid in a dental implant surface in vitro model | |
| Shibamoto et al. | Osteogenetic Effect of Low-Magnitude High-Frequency Loading and Parathyroid Hormone on Implant Interface in Osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110204 |